πΊπΈ #1 Export Destination
India's largest pharmaceutical partner
The United States is the single largest destination for Indian pharmaceutical products β $15.1B in the most recent year. That figure has grown 3.0Γ over the past decade, driven by demand for affordable generics and active pharmaceutical ingredients. The vast majority are finished medicines β drug formulations ready for dispensing.
Additional pharmaceutical categories from DGCIS β APIs, surgical, herbal, and more
India also supplied $518M in active pharmaceutical ingredients and bulk drugs to United States in 2025 (India-reported, DGCIS).
Total RBI-approved ODI commitments by Indian pharmaceutical companies into United States: $4.9B across 233 filings (2011-2026).
The relationship flows both ways. American pharmaceutical companies are among the largest investors in India's health ecosystem β operating manufacturing plants, R&D centres, and clinical trial networks across the country.